Nephrotic and nephritic syndromes. Find the injured compartment
Use protein loss, urine sediment, complement, and biopsy location to distinguish glomerular syndromes and choose the next diagnostic or treatment decision.
Two adults arrive with swollen ankles. One loses 7 g of protein a day and has fatty casts. The other has RBC casts, hypertension, and a rapidly rising creatinine. Edema describes what you see; it does not tell you where the filter is injured. Begin with the urine and the time course, then connect the pattern to the tissue.
Nephrotic and nephritic are syndromes, not mutually exclusive disease names. Heavy protein loss can coexist with glomerular inflammation. A disease label should explain the combination, including findings that seem inconvenient.
Describe the syndrome before naming the disease
Protein loss dominates
In adults, nephrotic-range proteinuria is conventionally more than 3.5 g per 24 hours. Nephrotic syndrome adds hypoalbuminemia, usually with edema; hyperlipidemia and lipiduria support the pattern. A spot urine protein-to-creatinine ratio estimates total protein loss but is affected by creatinine excretion. Confirm or refine the measurement when it will change treatment. Heavy proteinuria alone is not the complete syndrome. [1][2]
Inflammatory bleeding dominates
Dysmorphic RBCs, especially acanthocytes, and RBC casts support a glomerular source. Reduced filtration and sodium retention can produce oliguria, hypertension, and edema. Proteinuria varies and may reach the nephrotic range. Absence of casts in a single sample does not exclude GN; sample quality and timing matter. [1]
Hypoalbuminemia lowers plasma oncotic pressure, while primary kidney sodium retention also contributes to nephrotic edema. Do not assume every swollen patient is intravascularly depleted. Nephrotic thrombosis reflects several changes in coagulation and fibrinolysis. Urinary anticoagulant losses may contribute, but antithrombin deficiency is neither universal nor a sufficient explanation for hypercoagulability. [31] Loss of immune proteins and immunosuppressive treatment can increase infection risk. Lipid-laden cells and fatty casts, sometimes showing Maltese-cross birefringence, support lipiduria but do not identify a unique cause. [2]
Children need pediatric thresholds. KDIGO 2025 defines nephrotic-range proteinuria as a spot uPCR at least 2 g/g or at least 1000 mg/m²/day, with hypoalbuminemia below 3 g/dL, or edema if albumin is unavailable, defining the nephrotic syndrome. A child need not lose an adult-sized 3.5 g/day. [3]
Check blood pressure, creatinine trajectory, serum albumin, protein quantity, and microscopy together. Acute respiratory distress, dangerous hypertension, severe AKI, suspected thrombosis, or pulmonary bleeding changes the urgency before the exact disease name is settled.
Try it here · Checkpoint 1 of 3
Make your prediction before reading the choices. A first attempt is just a starting point.
Case 3
Show answer and explanations for case 3
A. It fails the definition unless a 24-hour sample exceeds 3.5 g (Why this does not fit)
The adult absolute threshold should not be imposed on a small child. Pediatric criteria account for body size or use uPCR.
B. It meets the pediatric nephrotic-range threshold (Best answer)
A uPCR at least 2 g/g meets the KDIGO pediatric threshold; low albumin and edema establish the accompanying syndrome.
C. It establishes a specific minimal change biopsy pattern (Why this does not fit)
The clinical pattern may support an empiric pathway, but protein quantity alone cannot identify histology.
D. It is consistent with isolated orthostatic proteinuria (Why this does not fit)
The first-morning sample reduces the effect of upright posture. Heavy protein in that sample, low serum albumin and edema support nephrotic syndrome rather than isolated orthostatic proteinuria.
Takeaway: Use the correct pediatric definition and preserve the test units.
Blood cells remain within the capillary under normal conditions.
Fenestrated endothelium
The subendothelial compartment lies between endothelium and basement membrane, on the blood-facing side.
Glomerular basement membrane
A shared extracellular support layer separates the endothelial and podocyte sides. Anti-GBM antibodies bind antigens in this layer.
Podocyte foot processes and slit diaphragms
The subepithelial compartment lies between basement membrane and podocytes, on the urinary side.
Bowman space
Filtrate enters the urinary space and then the proximal tubule. Podocytes face this space; the mesangium is a supporting region between capillary loops, not another serial filtration layer.
Read from blood toward urine. Location helps explain a pattern but is not a substitute for the full biopsy. [1][6][10][12]
Subendothelial immune deposits have ready access to circulating inflammatory systems, favoring a proliferative nephritic pattern. Subepithelial deposits often injure podocytes and produce prominent protein loss, as in membranous nephropathy. This is a useful tendency, not a rule without exceptions: postinfectious subepithelial humps occur in an inflammatory illness.
Light microscopy
Ask what the tissue is doing: proliferation, sclerosis, capillary wall thickening, crescents, or deposition. Focal means some glomeruli; diffuse means widespread involvement. Segmental means part of an individual glomerulus; global means the whole tuft.
Immunofluorescence
Ask what is deposited and how: granular immune staining, linear IgG, dominant IgA, full-house immunoreactants, C3 dominance, or little staining.
Electron microscopy
Ask where deposits lie and what the ultrastructure shows: foot process effacement, subepithelial deposits, mesangial deposits, or basement membrane splitting. Effacement is a podocyte injury response shared by several diseases.
Membranoproliferative GN, or MPGN, is a light-microscopic pattern with mesangial and capillary wall remodeling, often including duplicated contours. Classify its cause using immunofluorescence (IF) and clinical testing, rather than treating the older type I/II/III scheme as three complete diagnoses. Immune complexes suggest infection, autoimmunity, or monoclonal disease; C3-dominant staining prompts a complement-focused evaluation after infection is considered. [13]
Similar protein loss can require different treatment
The child and the adult are different starting points
A typical young child with edema, marked proteinuria, low albumin, preserved filtration, and no atypical features often receives glucocorticoids without an initial biopsy. Sustained hypertension, low complement, unexplained AKI, or other atypical findings call for further evaluation and possible biopsy. Steroid responsiveness describes a clinical course; it does not prove minimal change histology. Adults with suspected minimal change disease generally need biopsy. [3][4]
Minimal change disease has little change by light microscopy, usually no immune deposits by IF, and extensive foot process effacement on electron microscopy (EM). It can occur in adults, including with drugs such as NSAIDs or lymphoid disease. Initial glucocorticoids are standard in suitable adults, but response is not necessarily as rapid as in children. NSAIDs may also produce interstitial nephritis, sometimes alongside a podocyte lesion; a new drug plus AKI and pyuria should not be forced into a pure nephrotic diagnosis. [4][26]
FSGS names a scar, then asks why
Focal segmental glomerulosclerosis can reflect primary podocyte disease, genetic disease, viral injury, drugs, or adaptive stress from reduced nephron mass or obesity. IgM and C3 staining can occur in sclerotic segments and does not by itself establish a separate immune-complex GN. [35] Primary FSGS typically combines nephrotic syndrome with diffuse effacement after secondary and genetic causes are considered.
High-dose glucocorticoids are a first-line option for primary disease; a secondary adaptive lesion should receive cause-directed and supportive treatment rather than automatic immunosuppression. HIV-associated nephropathy can show collapsing glomerular injury, microcystic tubular dilation and endothelial tubuloreticular inclusions on EM; the inclusions are associated with interferon activity and are not specific to HIV. [33] Effective antiretroviral therapy is central.
Demographic categories do not establish the diagnosis. [5][7]
A separate 2026 US indication permits sparsentan to reduce proteinuria in FSGS in patients aged at least 8 years who do not have nephrotic syndrome. This does not establish it as a replacement for immunosuppression in primary nephrotic FSGS. Its label requires liver monitoring and pregnancy precautions, and existing RAS inhibitors and endothelin receptor antagonists must be discontinued before initiation. [29]
Membranous nephropathy requires two assessments
Subepithelial deposits and intervening basement membrane projections create the classic spike pattern. Granular IgG and C3 support immune deposition. In a compatible nephrotic presentation, positive anti-PLA2R can establish membranous nephropathy without biopsy in selected circumstances. Negative serum PLA2R does not exclude it; tissue testing or other antigens may matter. Evaluate associated infection, drugs, autoimmunity, and malignancy regardless of antibody status. [6]
Next assess progression and complication risk. Supportive care is necessary for everyone; immunotherapy is selected by risk and may use rituximab or other guideline-supported regimens. Glucocorticoid monotherapy is not the default. A suspicious lung mass warrants its own diagnostic evaluation, but its presence does not prove that every kidney finding is cancer-mediated. Thrombotic prophylaxis balances nephrotic severity against bleeding risk, with attention to the albumin assay used; it is not automatic for every patient. [6]
Use timing and complement to narrow immune disease
Hematuria with an infection or after it
IgA nephropathy often causes visible hematuria during a respiratory infection or within a few days. Complement levels are often normal; kidney biopsy demonstrates predominant or codominant mesangial IgA. Serum IgA alone cannot diagnose the disease. IgA vasculitis adds systemic small-vessel manifestations such as palpable purpura, abdominal pain, and arthralgia. [8][25]
For adults with IgAN, KDIGO 2025 treats persistent proteinuria of at least 0.5 g/day as meaningful progression risk in IgAN. The treatment goal is below 0.5, ideally below 0.3 g/day, alongside stable filtration. Optimized supportive care and disease-directed options depend on the individual. MEST-C histology informs prognosis but should not select a particular drug by itself. Do not reassure someone with 0.8 g/day merely because an older teaching threshold was 1 g/day. [8]
Poststreptococcal GN usually follows a latent interval, approximately 10 days after pharyngitis or up to 3 weeks after skin infection. Low C3, edema, hypertension, and glomerular hematuria fit the pattern; subepithelial humps may be seen on biopsy. Most children recover fully, but follow-up matters and adults fare less predictably. Control edema and blood pressure, assess AKI complications, and eradicate residual streptococci. Antibiotics do not directly reverse the established immune kidney lesion. Infection-related GN can also occur during an active infection, including endocarditis, so not every infection-associated case is delayed PSGN. [9][7]
Lupus can occupy more than one compartment
Full-house immunofluorescence means staining for IgG, IgA, IgM, C3, and C1q. In the right clinical context it supports lupus nephritis, but the biopsy must also report class, activity, and chronicity. Class I has mesangial deposits with normal light microscopy; class II adds mesangial proliferation. Class III involves fewer than half the glomeruli with proliferative lesions; class IV involves at least half. Class V is membranous and can coexist with III or IV. Class VI denotes advanced sclerosing disease. Prominent capillary immune deposits can produce wire-loop lesions; their interpretation belongs with the biopsy activity and chronicity assessment. [10][23]
Active III/IV disease, including mixed V, usually requires glucocorticoids plus a recommended immunosuppressive regimen, with options beyond a single drug pair. Hydroxychloroquine is recommended unless contraindicated; maintenance commonly uses a mycophenolic acid analogue. Isolated mesangial disease usually follows extrarenal treatment needs, while a nephrotic presentation may require assessment for lupus podocytopathy. Chronic scars and active inflammation are not interchangeable treatment targets. [10]
HCV cryoglobulinemic GN often combines an MPGN pattern, purpura, arthralgia, rheumatoid factor activity, and disproportionately low C4 from immune-complex complement activation. Stable kidney function without nephrotic syndrome generally permits direct-acting antivirals first. Cryoglobulinemic flare or rapidly progressive GN requires antivirals plus immunosuppression, sometimes plasma exchange. HBV-associated GN needs antiviral assessment as well; immunosuppression can reactivate untreated HBV. [14][7]
Try it here · Checkpoint 2 of 3
Make your prediction before reading the choices. A first attempt is just a starting point.
Case 35
Show answer and explanations for case 35
A. Start cyclophosphamide without treating the active HCV infection (Why this does not fit)
The active viral driver requires treatment, and the stable non-nephrotic presentation does not automatically call for cytotoxic induction.
B. Immediate plasma exchange in every HCV-associated GN (Why this does not fit)
Exchange is reserved for selected severe presentations rather than this stable phenotype.
C. Start DAAs with kidney and systemic monitoring (Best answer)
KDIGO recommends DAAs before additional treatment in stable HCV-associated GN without nephrotic syndrome. Reassess response and severity.
D. Observation until dialysis is necessary (Why this does not fit)
Treating the HCV driver can improve outcomes and should not wait for advanced kidney failure.
Takeaway: Stable HCV-associated GN and organ-threatening cryoglobulinemia need different treatment intensity.
Rapidly progressive GN describes a clinical decline, usually with an active sediment. Crescents reflect severe capillary injury with cells and fibrin in Bowman space; they are a severity pattern, not a unique disease. Obtain urgent nephrology assessment, serology and biopsy when appropriate while stabilizing dangerous electrolyte, respiratory, and volume complications.
Little immune staining
Pauci-immune necrotizing crescentic GN suggests ANCA-associated vasculitis, often associated with PR3 or MPO antibodies. Granulomatosis with polyangiitis often adds destructive upper airway or pulmonary disease; microscopic polyangiitis need not have that pattern. Some cases are ANCA-negative. Sparse deposits do not mean complement is biologically absent: C5a signaling participates in disease. [11]
Linear staining
Anti-GBM disease typically targets the NC1 domain of the alpha-3 component of type IV collagen and produces linear IgG along the glomerular basement membrane. [34] Pulmonary hemorrhage may occur, but renal-limited disease is real. Suspected severe disease warrants urgent treatment assessment without waiting for every confirmatory result. Plasma exchange, glucocorticoids, and cyclophosphamide are standard components; the poor-recovery exception requires dialysis at presentation, an adequate biopsy showing 100% crescents or more than 50% globally sclerosed glomeruli, and no pulmonary hemorrhage. [12]
Severe ANCA disease generally needs rituximab or cyclophosphamide plus a glucocorticoid strategy. KDIGO 2024 included avacopan as a selected glucocorticoid alternative, but this needs a dated qualification: on April 27, 2026, FDA proposed withdrawing its approval because efficacy was not established after problems with pivotal trial data. That FDA action was a proposal, not a completed US withdrawal.
FDA also warned of serious, sometimes fatal liver injury on March 31, 2026. In the EU, the revocation process reached a binding Commission decision on August 4, 2026; EMA advises no new starts and specialist transition of existing patients to alternatives. [30] Discuss alternatives and current regulatory guidance with the treating specialist; do not present avacopan as an uncomplicated steroid substitute. [27][28] Plasma exchange may be considered with creatinine above 3.4 mg/dL, dialysis requirement or rapidly increasing creatinine, or diffuse alveolar hemorrhage with hypoxemia.
It is an individualized adjunct, not a requirement for every ANCA-positive patient. Add plasma exchange for anti-GBM overlap. Rituximab or azathioprine commonly maintains ANCA remission; cyclophosphamide is not the routine long-term maintenance drug. Patients positive for both ANCA and anti-GBM antibodies need relapse planning consistent with their ANCA component. [11][12]
Keep systemic and inherited explanations in view
Diabetic kidney disease often develops gradually with albuminuria, mesangial expansion, basement membrane thickening, and sometimes nodular glomerulosclerosis. [24] Retinopathy supports a shared microvascular process but is not a pathognomonic kidney test. Sudden nephrotic syndrome, RBC casts, or rapid unexplained filtration loss should prompt assessment for another or additional disease. RAS blockade and SGLT2 therapy have roles in appropriate proteinuric CKD, alongside blood pressure and metabolic care. [22]
Amyloid is extracellular fibrillar protein deposition. Congo red with characteristic birefringence supports amyloid, but does not identify its protein type. AL amyloid derives from monoclonal immunoglobulin light chains; AA amyloid derives from serum amyloid A during sustained inflammation. A coincident plasma-cell or B-cell disorder is a reason to investigate, not permission to skip tissue typing.
Nonamyloid monoclonal immunoglobulin deposition, including deposition disease involving light chains (LCDD), can cause nodular sclerosis with Congo red-negative, nonfibrillar deposits. A weak albumin dipstick can also underestimate nonalbumin urinary protein; discordant total protein deserves quantitative testing, serum and urine immunofixation and serum free light chains. [16][17]
Persistent familial glomerular hematuria raises COL4A3, COL4A4, and COL4A5 disease. Alport ultrastructure may show thinning, thickening, and lamellation of the basement membrane. Hearing loss and ocular findings strengthen suspicion but can be absent. X-linked COL4A5 disease can affect women substantially; autosomal inheritance also occurs. Genetic testing and counseling clarify risk rather than assuming female relatives are unaffected carriers. [15]
Hematuria in sickle cell trait can reflect medullary sickling and papillary injury, but first assess infection, stones, glomerular disease, and malignancy. Trait does not make every episode benign. [18][32] After kidney donation, compensatory filtration in the remaining kidney is expected; neither a fixed fraction of baseline GFR nor inevitable FSGS after a set number of years is justified. Follow blood pressure, filtration, and urine albumin. [19]
Finally, not every scar starts in a glomerulus. Vesicoureteral reflux sends urine backward from bladder toward ureter and kidney. Recurrent upper urinary infection can accompany asymmetric scars and calyceal distortion. Chronic tubulointerstitial injury may contain dilated protein-filled tubules called thyroidization; this is not actual thyroid tissue and is not uniquely diagnostic of one cause. [20][21]
Try it here · Checkpoint 3 of 3
Make your prediction before reading the choices. A first attempt is just a starting point.
Case 16
Show answer and explanations for case 16
A. Start treatment for inflammatory AA amyloid based on the biopsy stain (Why this does not fit)
Congo red confirms an amyloid pattern but does not establish serum amyloid A as the precursor. Tissue typing is needed to direct the systemic evaluation and therapy.
B. Call it AL solely because any monoclonal protein is present (Why this does not fit)
A monoclonal protein can coexist with another amyloid type. Tissue typing is needed to avoid treating the wrong precursor.
C. Choose plasma-cell chemotherapy using only the serum monoclonal protein isotype (Why this does not fit)
A circulating clone can coexist with non-AL amyloid. The deposited protein must be identified before assuming that a plasma-cell regimen treats the renal deposits.
D. Type the amyloid deposits and evaluate the corresponding precursor disorder (Best answer)
Tissue typing, often with specialized methods, identifies the responsible protein and directs the appropriate hematologic or other systemic evaluation.
Takeaway: Proving amyloid and typing amyloid are separate diagnostic tasks.
A. Pure nephrosis because protein exceeds 3.5 g/day (Why this does not fit)
Heavy protein does not erase RBC casts or rapid filtration loss, which indicate active glomerular inflammation.
B. Nephritic disease with the low serum albumin explained by inflammation alone (Why this does not fit)
Inflammation can affect albumin, but 5.1 g/day urinary protein with hypoalbuminemia supplies nephrotic features. RBC casts and rapid filtration loss simultaneously establish an inflammatory glomerular pattern.
C. Mixed nephrotic-nephritic features needing urgent lupus nephritis assessment (Best answer)
The stem contains both protein-loss and inflammatory syndromes. Biopsy can reveal proliferative disease, membranous disease, or a combination.
D. Lower urinary bleeding with incidental edema (Why this does not fit)
RBC casts localize bleeding to the nephron and the renal deterioration is not explained by a lower tract source.
Takeaway: Syndrome overlap is useful information, not a contradiction to discard.
A. A calcineurin inhibitor as initial therapy before a steroid trial (Why this does not fit)
Calcineurin inhibitors have roles in steroid-resistant and selected relapsing disease. An uncomplicated first episode in this young child ordinarily begins with glucocorticoids and monitoring.
B. Routine kidney biopsy before selecting initial treatment (Why this does not fit)
Biopsy is important when features are atypical or steroid resistance develops. The supplied normal complement, filtration and blood pressure without systemic features support the usual empiric pediatric pathway.
C. Diuretics and salt restriction alone while waiting for spontaneous remission (Why this does not fit)
Edema care is useful but does not replace disease-directed treatment for an established first nephrotic episode. Spontaneous remission is not a dependable initial strategy.
D. Empiric glucocorticoid treatment with response and complication monitoring (Best answer)
The typical presentation supports initial steroid therapy without biopsy. Subsequent response guides classification and further evaluation.
Takeaway: A typical clinical phenotype can justify treatment without claiming histologic certainty.
A. Evaluate for an inflammatory glomerular cause and consider kidney biopsy (Best answer)
Low complement, active sediment, and AKI are atypical for the usual empiric steroid-sensitive childhood pathway and can change diagnosis and treatment.
B. Diagnose minimal change disease solely from the age (Why this does not fit)
Age does not outweigh the inflammatory findings. Assuming minimal change disease could delay cause-specific care.
C. Wait for several relapses before reviewing the diagnosis (Why this does not fit)
The atypical findings are present now and warrant evaluation during this episode.
D. Treat as uncomplicated steroid-sensitive disease until resistance is demonstrated (Why this does not fit)
Low complement, RBC casts, severe hypertension and unexplained AKI warrant investigation at presentation. It would be inappropriate to defer diagnostic assessment until a standard steroid course fails.
Takeaway: Atypical renal findings should interrupt an otherwise familiar pediatric pattern.
A. Use supportive care alone as for an adaptive FSGS lesion (Why this does not fit)
The nephrotic syndrome and diffuse effacement without a secondary explanation support primary FSGS. Supportive treatment remains necessary, but this phenotype can warrant glucocorticoids.
B. Use plasma exchange as initial treatment for the native-kidney lesion (Why this does not fit)
Plasma exchange is particularly relevant to some recurrent FSGS after transplantation. It is not the usual initial treatment for this newly diagnosed native-kidney primary phenotype.
C. Consider glucocorticoids for primary FSGS plus supportive care (Best answer)
The full syndrome supports primary FSGS, for which high-dose oral glucocorticoids are a guideline first-line option when suitable.
D. Start rituximab as the routine first-line induction agent (Why this does not fit)
Rituximab is not the guideline's routine first-line agent for primary FSGS. Glucocorticoids are recommended in suitable adults, with alternatives considered when contraindicated or ineffective.
Takeaway: Treat the cause of the FSGS lesion, not the acronym alone.
A. High-dose steroids automatically because the report says FSGS (Why this does not fit)
The adaptive context, preserved albumin, and limited effacement argue against treating this as primary nephrotic FSGS.
B. Escalate to cyclophosphamide as treatment for resistant primary disease (Why this does not fit)
This patient has not demonstrated steroid-resistant primary FSGS. The gradual non-nephrotic presentation, preserved albumin, glomerulomegaly and limited effacement support an adaptive process.
C. Observe without antiproteinuric treatment while albumin remains normal (Why this does not fit)
Normal serum albumin distinguishes this from full nephrotic syndrome but does not make 2.0 g/day proteinuria harmless. Adaptive stress, blood pressure and proteinuria still require treatment and follow-up.
D. Reduce adaptive stress with kidney-protective supportive care (Best answer)
Weight and blood pressure management and appropriate antiproteinuric treatment target the likely mechanism without unnecessary immunosuppression.
Takeaway: The absence of a full nephrotic syndrome can change how an FSGS biopsy is interpreted.
A. Start effective ART with specialist kidney care (Best answer)
The biopsy and virologic context support HIV-associated nephropathy. Suppressing HIV is central alongside other kidney care.
B. Use prednisone alone as the disease-directed treatment (Why this does not fit)
An immunosuppressive approach does not control untreated HIV replication. Effective ART is central in HIV-associated nephropathy; additional kidney therapies require individualized assessment.
C. Use RAS blockade alone while deferring viral treatment (Why this does not fit)
RAS blockade can help proteinuric CKD, but it does not address the uncontrolled viral driver. HIV-associated kidney disease warrants ART as well as kidney support.
D. Use rituximab as first-line treatment for a primary podocytopathy (Why this does not fit)
The uncontrolled HIV and collapsing glomerular and tubular pattern support HIV-associated nephropathy. Rituximab is not a substitute for effective antiviral therapy.
Takeaway: A secondary podocyte lesion needs treatment of its identified driver.
A. Positive PLA2R removes the need to investigate conditions associated with MN (Why this does not fit)
KDIGO still recommends evaluation for associated conditions, including malignancy and infection, regardless of PLA2R status.
B. Biopsy-free MN diagnosis in selected cases; assess associated causes and risk (Best answer)
A compatible nephrotic syndrome with positive anti-PLA2R can establish MN in selected circumstances. Risk assessment and secondary evaluation remain necessary.
C. Positive PLA2R establishes minimal change disease as the cause of nephrosis (Why this does not fit)
PLA2R autoantibodies are linked to membranous nephropathy rather than MCD.
D. Positive PLA2R requires immediate steroid monotherapy in every patient (Why this does not fit)
Immunotherapy is risk-based, and steroid monotherapy is not the default MN regimen.
Takeaway: A useful biomarker can reduce one diagnostic step without replacing the rest of the assessment.
A. Arrange appropriate tissue evaluation of the suspicious mass (Best answer)
The lesion needs a cancer workup in its own right and may be associated with MN. Its cause should be established rather than assumed.
B. Declare paraneoplastic MN proven without evaluating the mass (Why this does not fit)
A radiographic suspicion does not establish the mass histology or prove causation of the kidney disease.
C. Ignore the mass if PLA2R is positive (Why this does not fit)
Associated-condition assessment is still needed regardless of PLA2R result, especially with a suspicious clinical lesion.
D. Start kidney immunosuppression and reassess the mass only after proteinuria improves (Why this does not fit)
The spiculated mass and weight loss warrant prompt diagnostic evaluation independent of kidney response. Immunosuppression should not delay characterization of a possible malignancy.
Takeaway: Associated disease screening must lead to a real diagnostic evaluation when it finds an abnormality.
A. AA amyloidosis from sustained inflammatory precursor production (Best answer)
The typed precursor connects chronic inflammation to AA deposition. Management must address the underlying inflammatory source as well as kidney complications.
B. AL amyloidosis from a plasma-cell clone (Why this does not fit)
AL requires an immunoglobulin-derived precursor, whereas this tissue is specifically typed as serum amyloid A.
C. Monoclonal immunoglobulin deposition disease with nodular sclerosis (Why this does not fit)
Monoclonal deposition disease has a different precursor and is typically nonfibrillar and Congo red-negative. The typed serum amyloid A fibrils establish AA amyloid.
D. Dialysis-related beta-2 microglobulin amyloidosis (Why this does not fit)
That form has a different precursor and clinical setting, often involving joints after prolonged dialysis. Tissue typing here identifies serum amyloid A, not beta-2 microglobulin.
Takeaway: The precursor, not the generic deposit appearance, connects amyloid to treatment.
A. Extreme urine dilution has reduced all urinary protein concentrations (Why this does not fit)
The measured volume is 1.5 L with 3.0 g of protein, an average total protein concentration of 2 g/L. Dilution alone is not a convincing explanation for a trace albumin-sensitive result in the same collection.
B. Heavy albumin loss is being masked by a very low urine pH (Why this does not fit)
The stem supplies a normal pH and a functioning assay. The discrepancy should prompt testing for nonalbumin proteins rather than attributing it to a pH artifact.
C. Possible nonalbumin monoclonal protein excess requiring specific tests (Best answer)
Routine dipstick testing may miss substantial urinary light chains. Compare albumin with total protein and investigate with serum free light chains and serum/urine immunofixation.
D. The sample reflects transient isolated albuminuria after exertion (Why this does not fit)
The measured total protein and persistent discrepancy on a fresh aliquot warrant characterization. The monoclonal context particularly supports nonalbumin protein; the stem supplies no recent exertional trigger.
Takeaway: A protein screen has a detection preference; know what the assay can miss.
A. This proteinuria warrants risk-directed reassessment (Best answer)
Persistent proteinuria at least 0.5 g/day identifies risk in current guidance. Treatment aims below 0.5, ideally below 0.3 g/day.
B. Continue the same plan because preserved eGFR identifies a low-risk course (Why this does not fit)
Preserved eGFR does not negate persistent proteinuria. At 0.8 g/day, this adult exceeds the KDIGO 2025 risk threshold and warrants reassessment of supportive and disease-directed treatment.
C. Defer risk reassessment until proteinuria reaches the nephrotic range (Why this does not fit)
Progression risk is meaningful well below nephrotic-range proteinuria. KDIGO 2025 uses persistent proteinuria of at least 0.5 g/day for this adult risk discussion.
D. A single MEST-C score automatically determines one mandatory drug (Why this does not fit)
Histology informs prognosis but should not independently select a particular regimen without clinical context.
Takeaway: Do not retain an older risk threshold as a reason to dismiss persistent protein loss.
A. Immune thrombocytopenia explaining the systemic findings (Why this does not fit)
The platelet count is normal, and thrombocytopenia would not explain the characteristic systemic small-vessel and glomerular pattern.
B. IgA vasculitis with suspected renal involvement (Best answer)
Purpura, abdominal symptoms, arthralgia and glomerular urinary findings strongly suggest IgA vasculitis with renal involvement. This clinical pattern requires renal monitoring and assessment; it does not substitute for biopsy when histologic confirmation is needed.
C. Isolated minimal change disease (Why this does not fit)
A pure podocyte protein leak does not explain palpable purpura and inflammatory systemic symptoms.
D. Bladder infection as the unifying diagnosis (Why this does not fit)
Lower urinary infection does not explain the skin, joint, abdominal, and glomerular combination.
Takeaway: The same immunoglobulin-associated kidney injury can occur within a systemic vasculitis.
A. Treat as isolated class V and ignore the active proliferative component (Why this does not fit)
The proliferative component changes urgency and induction therapy; a membranous component does not cancel it.
B. Treat all biopsy findings as irreversible scar (Why this does not fit)
Active lesions are specifically described and may respond to immunosuppression; activity differs from chronicity.
C. Use an active proliferative lupus nephritis regimen with supportive care and hydroxychloroquine when appropriate (Best answer)
Class III/IV with or without V requires a proliferative-disease strategy, typically glucocorticoids plus a guideline-supported immunosuppressive regimen.
D. Use hydroxychloroquine alone for the severe active renal lesion (Why this does not fit)
Hydroxychloroquine is valuable background therapy but is not sufficient induction for severe active proliferative nephritis.
Takeaway: Mixed histology requires treating the clinically consequential active component.
A. Pauci-immune denotes abundant granular deposits formed by immune complexes (Why this does not fit)
It describes little or no immune staining, unlike a deposit-rich immune-complex pattern.
B. Normal serum complement rules out ANCA vasculitis as the cause of this lesion (Why this does not fit)
Normal circulating complement is common and does not exclude tissue-level complement pathway participation.
C. This pauci-immune biopsy pattern establishes anti-GBM disease as the cause (Why this does not fit)
Anti-GBM disease typically has linear IgG staining rather than a pauci-immune pattern.
D. Sparse deposits do not rule out complement activity, including C5a (Best answer)
ANCA-related neutrophil injury involves inflammatory amplification through complement. Deposit appearance is not a complete inventory of active biology.
Takeaway: Pauci-immune describes staining, not the absence of every immune pathway.
A. Rituximab or cyclophosphamide with an appropriate glucocorticoid strategy (Best answer)
These are guideline induction options for severe ANCA-associated vasculitis. Selection incorporates renal severity, infection risk, fertility, prior exposure, and preferences.
B. Azathioprine alone as immediate induction (Why this does not fit)
Azathioprine is commonly a maintenance option after remission, not sufficient initial therapy for this organ-threatening presentation.
C. Antibiotics alone because the sinus is involved (Why this does not fit)
Infection must be assessed, but the PR3-positive necrotizing renal process supports systemic vasculitis requiring immunotherapy.
D. ACE inhibition alone until creatinine reaches dialysis levels (Why this does not fit)
Supportive antiproteinuric care does not control this active destructive vasculitis and should not delay induction.
Takeaway: Severe active vasculitis needs induction therapy; maintenance drugs answer a later question.
A. Exclude it whenever anti-GBM antibodies are absent, regardless of disease severity (Why this does not fit)
KDIGO permits consideration in severe ANCA kidney disease and hypoxemic alveolar hemorrhage even without anti-GBM antibodies.
B. Consider it for severe kidney disease and hypoxemic lung hemorrhage (Best answer)
These are settings in which the potential benefits and risks of plasma exchange warrant specialist assessment. It is not an automatic intervention for every ANCA case.
C. Use it in place of remission-induction immunotherapy to control the disease (Why this does not fit)
Plasma exchange, when used, is additional therapy and does not replace control of ongoing autoimmune disease.
D. Require it for every patient with a positive ANCA titer, regardless of severity (Why this does not fit)
Clinical severity and disease context, not antibody positivity alone, determine the decision.
Takeaway: Plasma exchange in ANCA disease is a severity-dependent consideration.
A. Begin urgent specialist-directed treatment without waiting for every confirmatory result (Best answer)
Anti-GBM injury can progress quickly. Plasma exchange, glucocorticoids, and cyclophosphamide are standard components when indicated, alongside stabilization.
B. Wait several weeks to see whether hematuria resolves spontaneously (Why this does not fit)
Delay risks irreversible kidney injury and ongoing pulmonary hemorrhage. This is not a mild observation-only syndrome.
C. Use rituximab alone as the universal standard first-line regimen (Why this does not fit)
The standard initial approach includes antibody removal and suppression with glucocorticoids and cyclophosphamide; alternatives are specialist decisions.
D. Withhold therapy solely because dialysis has started despite active pulmonary hemorrhage (Why this does not fit)
Pulmonary hemorrhage is a major reason to treat; the selected poor-renal-recovery exception does not apply in the same way when lung bleeding is present.
Takeaway: Time-sensitive autoimmune injury can require treatment while confirmation is completed.
A. All antibodies now confer the same negligible relapse risk (Why this does not fit)
The ANCA component can confer relapse risk beyond the usual course of isolated anti-GBM disease.
B. Plan ANCA-directed relapse surveillance and maintenance (Best answer)
KDIGO recommends maintenance as for ANCA vasculitis in double-positive disease, after the acute anti-GBM-directed treatment phase.
C. Ignore PR3 because linear IgG was found (Why this does not fit)
One biopsy pattern does not erase clinically relevant coexisting ANCA autoimmunity.
D. Use scheduled plasma exchange as the sole relapse-prevention treatment (Why this does not fit)
Exchange addresses circulating pathogenic antibody in the acute phase. The ANCA component needs its own relapse surveillance and maintenance plan; serial exchange is not a substitute.
Takeaway: Double-positive disease combines an urgent anti-GBM problem with an ANCA relapse problem.
B. Proof of an isolated inherited alternative-pathway defect (Why this does not fit)
That may be relevant to some C3-dominant diseases, but the HCV cryoglobulin context and low C4 support immune-complex classical activation.
C. Urinary loss of albumin as the only cause of complement change (Why this does not fit)
Protein loss alone does not best explain the characteristic C4 consumption in this systemic immune-complex syndrome.
D. Reduced complement production as the primary explanation from advanced liver failure (Why this does not fit)
Low synthesis can affect complement in advanced hepatic dysfunction, but no such failure is supplied. Mixed cryoglobulinemia with systemic vasculitis and an MPGN pattern favors classical-pathway consumption.
Takeaway: Complement consumption can identify the kind of immune process occurring.
A. Trait can cause medullary sickling, but alternative causes of hematuria must be investigated (Best answer)
Sickle trait can be associated with papillary injury; the diagnosis should not prevent assessment for infection, stones, glomerular disease, or malignancy.
B. Papillary injury is possible only with HbSS (Why this does not fit)
Renal complications and hematuria can occur in sickle trait, particularly in the vulnerable medullary environment.
C. Every episode in HbAS is benign and needs no assessment (Why this does not fit)
CDC advises a comprehensive evaluation before attributing hematuria to trait. Serious alternative causes can occur.
D. Papillary injury proves an immune-complex glomerulonephritis (Why this does not fit)
The papilla is not the glomerular capillary tuft, and this lesion does not establish immune deposits.
Takeaway: Trait is a possible contributor, not a substitute for a hematuria workup.
A. An acquired antiphospholipid antibody disorder (Why this does not fit)
Antiphospholipid antibodies can cause venous thrombosis, but the stem provides no evidence of that disorder. Severe nephrotic protein loss already supplies a strong, multifactorial prothrombotic mechanism.
B. Monoclonal immunoglobulin-associated hyperviscosity (Why this does not fit)
A monoclonal protein disorder can cause hyperviscosity, but none is supplied. Heavy nephrotic protein loss and membranous disease favor altered anticoagulant and procoagulant balance.
C. Immune thrombotic thrombocytopenic purpura (Why this does not fit)
TTP produces a thrombotic microangiopathy with thrombocytopenia and microangiopathic hemolysis, rather than isolated renal vein thrombosis explained by nephrotic physiology.
D. A multifactorial nephrotic imbalance of coagulation and fibrinolysis (Best answer)
Severe nephrotic syndrome alters several hemostatic pathways. Urinary anticoagulant losses may contribute, but antithrombin deficiency is not universal and should not be assumed from albumin or proteinuria alone.
Takeaway: Nephrotic thrombosis is multifactorial; an acute confirmed clot requires treatment assessment.
A. Individualize clot-versus-bleeding risk assessment with a specialist (Best answer)
Marked nephrosis increases clot risk, but recent major bleeding changes the net benefit. Albumin values also depend on the assay and cannot be used as a universal isolated trigger.
B. Begin prophylaxis now using hypoalbuminemia as the deciding criterion (Why this does not fit)
Albumin helps estimate thrombotic risk, but recent major bleeding is a major competing hazard. The decision requires individualized assessment rather than albumin alone.
C. Use aspirin as an equivalent substitute for venous thrombosis prophylaxis (Why this does not fit)
Aspirin is not equivalent to anticoagulation for preventing nephrotic venous thrombosis and still carries bleeding risk. It does not bypass the need to assess the recent gastrointestinal bleed.
D. Postpone the decision until eGFR falls below 30 (Why this does not fit)
Nephrotic thrombosis risk is not confined to advanced filtration loss. Assess the current nephrotic severity and bleeding history without waiting for an arbitrary eGFR threshold.
Takeaway: Preventive anticoagulation is a benefit-risk decision, separate from treating an established clot.
A. The nephrotic protein level rules out an interstitial lesion (Why this does not fit)
NSAID-associated injury can combine interstitial nephritis with a minimal change pattern. Both compartments are abnormal in the biopsy.
B. Drug-associated interstitial nephritis plus a podocyte lesion (Best answer)
The exposure, AKI, pyuria, interstitial inflammation and effacement support a combined drug-associated process. Withdraw the suspected drug and assess further treatment.
C. Pure hemodynamic NSAID injury explains the inflammatory biopsy completely (Why this does not fit)
NSAIDs can reduce perfusion, but a hemodynamic effect alone does not explain interstitial inflammatory infiltrates.
D. Membranous nephropathy established by effacement alone (Why this does not fit)
Effacement is not specific, and the subepithelial immune deposits needed to support MN are absent.
Takeaway: A medication can injure more than one kidney compartment at once.
